Page last updated: 2024-09-05

symmetric dimethylarginine and Left Ventricular Hypertrophy

symmetric dimethylarginine has been researched along with Left Ventricular Hypertrophy in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atzler, D; Böger, RH; Chen, P; Chen, Y; Fassett, J; Guo, H; Hu, X; Kwak, D; Liu, X; Lu, Z; Schwedhelm, E; Wang, H; Xu, X; Yue, W; Zhang, P1

Other Studies

1 other study(ies) available for symmetric dimethylarginine and Left Ventricular Hypertrophy

ArticleYear
Cardiomyocyte dimethylarginine dimethylaminohydrolase-1 (DDAH1) plays an important role in attenuating ventricular hypertrophy and dysfunction.
    Basic research in cardiology, 2017, 08-17, Volume: 112, Issue:5

    Topics: Amidohydrolases; Animals; Arginine; Atrial Natriuretic Factor; Disease Models, Animal; Fibrosis; Genetic Predisposition to Disease; Hypertrophy, Left Ventricular; Male; Mice, Knockout; Myocytes, Cardiac; Nitric Oxide; Phenotype; Signal Transduction; Tyrosine; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling

2017